Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cymabay Therapeutics
(NQ:
CBAY
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Cymabay Therapeutics
< Previous
1
2
3
4
Next >
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
March 15, 2024
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a...
Via
Benzinga
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
March 14, 2024
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
February 13, 2024
Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800...
Via
Benzinga
Fear & Greed Index Remains In 'Extreme Greed' Zone Ahead Of Inflation Data; Dow Hits Record high
February 13, 2024
The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Monday. U.S. stocks closed mixed on Monday, with the Dow Jones index climbing to a fresh high during the session.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
February 12, 2024
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
6 Analysts Have This to Say About CymaBay Therapeutics
December 15, 2023
Via
Benzinga
Recap: CymaBay Therapeutics Q3 Earnings
November 07, 2023
Via
Benzinga
Dow Up Triple Digits, Hits Fresh Highs
February 12, 2024
Stocks are on the rise today, as investors towards tomorrow's inflation data.
Via
Talk Markets
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Why is CymaBay (CBAY) Stock Up 25% Today?
February 12, 2024
CymaBay stock is rising higher on Monday as CBAY investors react to a $4.3 billion acquisition deal with Gilead Sciences.
Via
InvestorPlace
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
February 12, 2024
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics
February 12, 2024
Via
Benzinga
Earnings Outlook For CymaBay Therapeutics
November 06, 2023
Via
Benzinga
Where CymaBay Therapeutics Stands With Analysts
November 06, 2023
Via
Benzinga
Why CymaBay Therapeutics Stock Is Sinking This Week
September 21, 2023
The stock has given up some of its gains but remains up more than 130% year to date.
Via
The Motley Fool
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
February 12, 2024
Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA priority review was granted, and there is potential for significant revenue...
Via
Benzinga
Exposures
Product Safety
CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition
February 12, 2024
The company is working on a treatment for primary biliary cholangitis, a liver disease treatment.
Via
Investor's Business Daily
Why CymaBay Morphed From Dollar Stock To Biotech Rocket
December 28, 2023
The company is working on the first treatment that could make a difference in the itching associated with a liver disease.
Via
Investor's Business Daily
Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
November 08, 2023
Via
Benzinga
Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today
October 23, 2023
It became increasingly likely that seladelpar will ultimately gain regulatory approval.
Via
The Motley Fool
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
September 27, 2023
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.
Via
InvestorPlace
UBS Maintains Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
September 26, 2023
Via
Benzinga
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
September 21, 2023
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due...
Via
Benzinga
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday
September 12, 2023
The company is about to reap more money than previously expected from a new capital-raising effort.
Via
The Motley Fool
Why CymaBay Therapeutics Stock Popped Again Today
September 11, 2023
Days after it reported highly encouraging news from a clinical trial, the company announced a new round of capital-raising.
Via
The Motley Fool
Why Hooker Furnishings Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 08, 2023
Gainers Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics.
Via
Benzinga
Why CymaBay Therapeutics Stock Is Jumping Today
September 08, 2023
The momentum continues after CymaBay reported great clinical results on Thursday.
Via
The Motley Fool
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
September 08, 2023
The company is working on a treatment for a liver disease that can cause severe itching.
Via
Investor's Business Daily
Smartsheet, Kroger, Lantronix And Other Big Stocks Moving Higher On Friday
September 08, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. Lantronix, Inc. (NASDAQ: LTRX) shares jumped 26.3% to...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
CymaBay Therapeutics' Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage
September 07, 2023
CymaBay Therapeutics Inc (NASDAQ: CBAY) released topline results from its Phase 3 pivotal RESPONSE study of seladelpar for adult patients with
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 07, 2023
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.